Cut Down on Oncology Drug Waste With Better Forecasting

Why It Matters

Reducing drug waste directly improves pharma margins, lowers patient out‑of‑pocket costs, and supports sustainable healthcare delivery. Advanced forecasting offers a scalable lever to meet regulatory demands and enhance supply chain efficiency.

Key Takeaways

• 30% of oncology drugs discarded each year
• CMS refunds manufacturers when waste exceeds 10% threshold
• AI-driven forecasts cut prediction error versus traditional models
• Accurate demand planning lowers stockpiles and costs
• Data insights can justify new, patient‑aligned packaging

Pulse Analysis

The scale of oncology drug waste—estimated at 30% of vials—creates a dual burden for manufacturers and patients. Beyond the obvious financial loss, the CMS Discarded Drug Refund Program now obligates companies to reimburse Medicare for excess waste, turning inefficiency into a regulatory liability. Traditional demand planning, anchored in historical sales and static epidemiology, fails to capture the dynamic nature of modern oncology regimens, leaving supply chains vulnerable to over‑production and costly stockpiles.

Artificial intelligence and advanced analytics are reshaping this landscape by ingesting longitudinal claims, electronic health records, and real‑world dosing parameters such as weight and body surface area. Pilot projects have demonstrated that AI‑driven models can predict drug utilization within a 2‑3% margin of CMS‑reported waste, far outperforming legacy methods. By continuously updating forecasts as new therapies emerge or treatment patterns shift, these models enable manufacturers to align production schedules with actual clinical demand, reducing both excess inventory and the risk of drug expirations.

The ripple effects extend beyond cost savings. More precise forecasts empower stakeholders to advocate for packaging redesigns—such as multi‑dose vials or size‑tailored containers—that match real‑world usage, further curbing waste. As the technology matures, its application can broaden to other specialty biologics, immunotherapies, and rare‑disease treatments, fostering a more resilient, patient‑centric supply chain. In an era where regulatory scrutiny and payer pressures intensify, AI‑enhanced forecasting emerges as a strategic imperative for sustainable growth.